News | Proton Therapy | September 02, 2015

Southern Hemisphere’s First Proton Therapy Unit Developing in South Australia

Clinicians working with Philips to bring more precise radiation therapy option to 600-800 patients annually  

SAHMRI, proton therapy unit, South Australia, first in Southern Hemisphere

September 2, 2015 — Significant national and international momentum is building to include a proton therapy unit as part of the planned expansion of SAHMRI, South Australia’s Health and Medical Research Institute. It would be the first facility in the Southern Hemisphere to deliver proton therapy.

Cancer specialist and former CEO of Cancer Council Australia Prof. Ian Oliver said South Australia was the obvious choice to create a Proton Therapy Unit that would service Australia and the region.

“There have been groups in New South Wales and Victoria also considering a bid to establish a proton facility, but South Australia is the furthest ahead,” he said.

“Because SAHMRI already operates a cyclotron, it already has highly relevant experience in operating a particle accelerator as would be required for proton therapy,” he added.

For proton therapy, a cyclotron accelerates the protons almost to the speed of light, and they are then directed through a probe to release their energy at the tumor site.

“The treatment itself takes less than two minutes,” said Prab Takhar, director of the molecular imaging and therapy research unit at SAHMRI.

Radiation oncologists across South Australia are collaborating with Philips on development of the center, which will expand the number of trained technicians available when the center opens.

The SAHMRI proton therapy unit will reportedly be able to treat 600-800 patients per year.

For more information: www.sahmri.com

Related Content

ProCure Proton Therapy Center New Jersey Celebrates Five-Year Cancer-Free Milestone for Prostate Cancer Patients
News | Proton Therapy | September 20, 2017
ProCure Proton Therapy Center in Somerset, N.J., recently celebrated the five-year cancer-free milestone for the first...
Varian to Showcase Latest Radiation Therapy Technologies and Software at ASTRO 2017
News | Radiation Therapy | September 19, 2017
Varian Medical Systems announced it will be demonstrating its new Halcyon platform and HyperArc high-definition...
Elekta to Highlight MOSAIQ Oncology Analytics at ASTRO Annual Meeting
News | Radiation Therapy | September 19, 2017
September 19, 2017 — Elekta will highlight its Mosaiq Oncology...
Double Targeting Ligands to Identify and Treat Prostate Cancer

The mice were imaged with small-animal PET/CT using 124I-RPS-027 (7.4 MBq [200 μCi]). Credit: JM Kelly et al., Department of Radiology, Weill Cornell Medicine, New York, NY

News | Prostate Cancer | September 14, 2017
Researchers have demonstrated a new, effective way to precisely identify and localize prostate cancer tumors while...
Clinical Trials and Cutting-Edge Radiation Oncology Research to Be Featured at ASTRO 2017
News | Radiation Therapy | September 14, 2017
The program for the 2017 Annual Meeting of the American Society for Radiation Oncology (ASTRO), Sept. 24-27 in San...
Provision Healthcare Joins RayCare Clinical Partners
News | Oncology Information Management Systems (OIMS) | September 11, 2017
Provision, located in Knoxville, Tenn., is the latest to partner with RaySearch Laboratories on the development of its...
U.K.'s NICE Supports Use of Hydrogel Spacer in Prostate Cancer Treatement
News | Patient Positioning Radiation Therapy | September 08, 2017
Augmenix Inc. announced that the National Institute for Health and Care Excellence (NICE) in the U.K. has issued...
Sponsored Content | Videos | Radiation Therapy | September 08, 2017
The new Visicoil MR is a helically-wound, flexible linear fiducial marker.
The IBA Proteus Plus

The IBA Proteus Plus.

Feature | Proton Therapy | September 08, 2017 | By Jeff Zagoudis
As one of the more precise methods of delivering radiation therapy for cancer treatment, proton therapy has grown at a...
FDG-PET/CT Predicts Melanoma Patients' Response to Immune Checkpoint Inhibitor Therapy
News | PET-CT | September 07, 2017
September 7, 2017 — Advanced melanoma has a poor prognosis, but immune checkpoint inhibitor therapy can be effective
Overlay Init